Insider Trading November 20, 2026 11:01 PM

Lipocine Director John Higuchi Purchases $225,225 in Company Stock

The two-day buying spree comes as shares trade near a 52-week low and the company advances its Phase 3 BLOOM trial for LPCN1154.

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
LPCN

Lipocine director John W. Higuchi acquired 150,000 shares over two days for $225,225, with prices ranging from $1.4911 to $1.5119. The purchases increase his direct holdings to 391,365 shares. The stock is near its 52-week low of $1.36 and has fallen 13% over the past week. Lipocine recently initiated its Phase 3 BLOOM trial for LPCN1154, targeting severe postpartum depression, with the first participant expected to be dosed in early Q4 2026. H.C. Wainwright maintains a Neutral rating and $4.00 price target. The company also updated its sales agent fee agreement with A.G.P./Alliance Global Partners, setting the fee at up to 3.0%.

Lipocine Director John Higuchi Purchases $225,225 in Company Stock
LPCN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Director John W. Higuchi acquired 150,000 shares over two days for $225,225, increasing his direct holdings to 391,365 shares.
  • The purchases come as Lipocine's stock trades near its 52-week low of $1.36 and has declined 13% over the past week.
  • Lipocine recently initiated its Phase 3 BLOOM trial for LPCN1154 and updated its sales agent fee agreement with A.G.P./Alliance Global Partners.
  • Analysts maintain price targets ranging from $4 to $6 per share, with H.C. Wainwright holding a Neutral rating and $4.00 target.

John W. Higuchi, a director at Lipocine Inc. (NASDAQ: LPCN), has disclosed the acquisition of $225,225 in company common stock through two separate transactions, according to a regulatory filing.

The purchases were executed on consecutive days. On November 19, 2026, Mr. Higuchi bought 75,000 shares, and on November 20, 2026, he acquired an additional 75,000 shares. The acquisition prices ranged from $1.4911 to $1.5119 per share. Following these transactions, Mr. Higuchi directly holds 391,365 shares of Lipocine common stock.

The insider buying occurred as Lipocine's shares trade near their 52-week low of $1.36, with the stock down 13% over the past week. According to InvestingPro analysis, LPCN appears undervalued at current levels, suggesting the director may be capitalizing on the recent weakness. The company's market capitalization stands at $16.61 million, and analysts maintain price targets ranging from $4 to $6 per share. InvestingPro offers 7 additional exclusive tips for LPCN subscribers, along with comprehensive Fair Value analysis.

In other recent developments, Lipocine Inc. announced the initiation of its Phase 3 BLOOM trial for LPCN1154, aimed at treating severe postpartum depression. This trial marks a significant step as the company plans to dose the first participant in the early fourth quarter of 2026. Meanwhile, H.C. Wainwright has maintained a Neutral rating for Lipocine, with a price target set at $4.00, following the trial announcement. Additionally, Lipocine has updated its sales agent fee agreement with A.G.P./Alliance Global Partners. The new agreement stipulates that the fee for sales under their existing Sales Agreement will be up to 3.0%, with potential adjustments by mutual agreement. This update was formalized in a recent SEC filing dated September 8, 2026. These developments reflect ongoing strategic moves by Lipocine in its clinical and financial operations.

Lipocine's stock closed at $1.48, down $0.0200 or 1.33%, on the day of the disclosure. In after-hours trading, the shares rose to $1.53, up $0.0500 or 3.38%.

Risks

  • The stock is trading near its 52-week low and has experienced recent price weakness, which could persist.
  • The Phase 3 BLOOM trial for LPCN1154 carries inherent clinical and regulatory risks, with first participant dosing planned for early Q4 2026.
  • Analyst ratings and price targets may change based on trial outcomes and other developments.

More from Insider Trading

Legend Biotech CEO Ingrid Zhang Buys $163,200 in Shares Near 52-Week Low Nov 21, 2026 Home Depot Chair Decker Offloads $6.55 Million in Shares Following Option Exercise Nov 20, 2026 Peloton Accounting Chief Offloads Shares Under Pre-Set Trading Plan Nov 20, 2026 Peloton COO Offloads $35,736 in Shares Under Pre-Set Trading Plan Nov 20, 2026 Cross Timbers Royalty Trust Director Expands Stake with $72,264 in Unit Purchases Nov 20, 2026